Application of CTC-derived spheroid for drug screening toward personalized treatment in patients with breast cancer
Translational Oncology · 2026-01 · 63 · 102573
DOI: 10.1016/j.tranon.2025.102573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Oncology, 2026-01. Verfasst von Hsu-Huan Chou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery and Breast surgery, Chang Gung Memorial Hospital Linkou branch, Taoyuan 33305, Taiwan; Graduate Institute of Clinical M…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Chang Gung Medical Foundation, Chang Gung Memorial Hospital.
Abstract (Originalsprache)
PURPOSE: Tumor heterogeneity and drug resistance remain key challenges in breast cancer management. While organoid cultures can be established from resected tumor specimens, patients undergoing systematic treatment often lack accessible tissue for ex vivo drug testing. Circulating tumor cells (CTCs) offer a minimally invasive alternative. The purpose of this study was to establish a clinically feasible workflow that integrates CTC enumeration and CTC-derived spheroid drug screening to overcome the limitations of tissue-dependent organoid models and enable personalized treatment in breast cancer. METHODS: CTCs were isolated from 34 newly diagnosed breast cancer patients using a liposome-tethered supported lipid bilayer (LIPO-SLB) microfluidic platform functionalized with anti-EpCAM antibodies. Thirteen patients undergoing systemic therapy and relapse were further assessed using CTC-spheroid culture for ex vivo drug screening. Hormone receptor expression and genomic mutation profiles were integrated with drug testing. One relapsed case underwent pre- and post-treatment spatial transcriptomic analysis (Xenium in situ). RESULTS: CTC and CTC-cluster counts significantly declined post-treatment in responders (p=0.044 and p=0.0264, respectively), but not in non-responders. CTC-spheroids were successfully generated in all 13 cases, enabling ex vivo drug testing. Effective therapies were identified in 9 patients (69.2%), of whom 7 achieved partial responses and 1 achieved stable disease; one patient did not receive the suggested treatment. Ex vivo drug sensitivity results correlated with clinical outcomes. Integrating CTC-based drug testing, hormone receptor expression in CTCs, and genomic DNA mutation profile further improved prediction of radiological response. Spatial transcriptomics revealed therapy-induced clonal shifts, with resistant subpopulations characterized by over-expression of chemoresistant gene, EIF4EBP1. CONCLUSION: This study demonstrates that CTC-derived spheroid drug screening provides actionable therapeutic guidance when tissue is unavailable. Combined with hormone receptor and genomic profiling, this liquid biopsy-based platform enables personalized treatment, and dynamic monitoring of resistance in breast cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery and Breast surgery, Chang Gung Memorial Hospital Linkou branch, Taoyuan 33305, Taiwan; Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan 33302, Taiwan.
- Genomics Research Center, Academia Sinica, Taipei 11520, Taiwan.
- Department of General Surgery and Breast surgery, Chang Gung Memorial Hospital Linkou branch, Taoyuan 33305, Taiwan.
- Genomics Research Center, Academia Sinica, Taipei 11520, Taiwan; AcroCyte Therapeutics Inc., New Taipei City 22175, Taiwan.
- Department of Anatomic Pathology, Chang Gung Memorial Hospital Linkou branch, Chang Gung University, College of Medicine, Taoyuan City 33302, Taiwan.
- Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Taoyuan 33302, Taiwan.
Förderung
- National Science and Technology Council
- Chang Gung Medical Foundation
- Chang Gung Memorial Hospital
Zitieren
APA
Chou, H. H., Che, T. F., Lee, K. J., Chen, S. C., Chen, J. Y., Huang, Y. J., Lim, S. C., Huang, S. C., Tsai, C. L., Chang, Y. C., & Tsai, C. N. (2026). Application of CTC-derived spheroid for drug screening toward personalized treatment in patients with breast cancer. Translational Oncology, 63, 102573. https://doi.org/10.1016/j.tranon.2025.102573
Vancouver
Chou HH, Che TF, Lee KJ, Chen SC, Chen JY, Huang YJ, et al. Application of CTC-derived spheroid for drug screening toward personalized treatment in patients with breast cancer. Translational Oncology. 2026;63:102573. doi:10.1016/j.tranon.2025.102573
BibTeX
@article{Chou2026,
author = {Chou, Hsu-Huan and Che, Ting-Fang and Lee, Kuan-Ju and Chen, Shin-Cheh and Chen, Jia-Yang and Huang, Yen-Jang and Lim, Syer Choon and Huang, Shih-Chiang and Tsai, Chia-Lung and Chang, Ying-Chih and Tsai, Chi-Neu},
title = {Application of CTC-derived spheroid for drug screening toward personalized treatment in patients with breast cancer},
journal = {Translational Oncology},
year = {2026},
volume = {63},
pages = {102573},
doi = {10.1016/j.tranon.2025.102573}
}
EUVIMED